The Prognostic Value of Hormone Receptor Detection by Enzyme Immunoassay and Immunohistochemistry: A Prospective Study in Patients with Early Breast Cancer
Free accessResearch articleFirst published online January, 2002
The Prognostic Value of Hormone Receptor Detection by Enzyme Immunoassay and Immunohistochemistry: A Prospective Study in Patients with Early Breast Cancer
The main reason to determine estrogen (ER) and progesterone receptors (PR) in breast cancer is their predictive value for the response to endocrine therapy. In addition, ER and PR are often used as prognostic indicators. Enzyme immunoassay (EIA) and immunocytochemical assay (ICA) are two methods for determining ER and PR. These two methods have not been compared with each other in relation to clinical endpoints. In the present study we prospectively evaluated the prognostic value of ER and PR as determined by ICA and EIA in 223 and 207 patients, respectively, with early breast cancer. ER was positive in approximately 77% of patients, while PR was positive in approximately 65% of patients. The proportion of potential agreement beyond chance between EIA and ICA was 0.58 and 0.65 for ER and PR, respectively. The median follow-up was 86 months. Both ER and PR appeared to be weak prognostic factors. There were no differences in prognostic value according to the time point of analysis or cutoff value chosen, nor were there any differences in the prognostic value of hormone receptors detected by ICA or EIA. Both methods appear to be equivalent in terms of qualification and prognostic value.
Early Breast Cancer Trialists’ Group:Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet1998; 351: 1451–67.
2.
GoldhirschA., GlickJ.H., GelberR.D., CoatesA.S., SennH-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol2001; 19: 3817–27.
3.
PichonM.F., BroetP., MagdelnatH.Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer1996; 73: 1545–51.
4.
AllredD.C., HarveyJ.M., BerardoM., ClarkG.M.Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol1998; 11: 155–68.
5.
BeckT., WeikelW., BrummC., WilkensC., PollowK., KnapsteinP-G. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): Prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol1994; 53: 220–7.
6.
HannaW., MobbsB.G.Comparative evaluation of ER-ICA and enzyme immunoassay for the quantitation of estrogen receptors in breast cancer. Am J Clin Pathol1989; 91: 182–6.
7.
AasmundstadT.A., HaugenO.A., JohannesenE., HoeA.L., KvinnslandS.Estrogen receptor analysis: Correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol1992; 45: 125–9.
8.
McClellandR.A., WilsonD., LeakeR., FinlayP., NicholsonR.I.A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer1991; 27: 711–5.
9.
TeschM., ShawwaA., HendersonR.Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol1993; 99: 8–12.
10.
BlankensteinM.A.Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group. Breast Cancer Res Treat1990; 17: 91–8.
11.
FoekensJ.A., PortengenH., van PuttenW.L.J., PetersH.A., KrijnenHLJM, Alexieva-FiguschJ., KlijnJ.G.M.Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res1989; 49: 5823–8.
12.
CavaliereA., BucciarelliE., SidoniA., BianchiG., PietropaoliN., LudoviniV., VitaliR.Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay. Cytometry1996; 26: 204–8.
13.
Saccani JottiG., JohnstonS.R.D., SalterJ., DetreS., DowsettM.Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol1994; 47: 900–5.
14.
HeubnerA., BeckT., GrillH-J, PollowK.Comparison of immunocytochemical estrogen receptor assay, estrogen receptor enzyme immunoassay, and radioligand-labeled estrogen receptor assay in human breast cancer and uterine tissue. Cancer Res1986; 46: 4291s–5s.
15.
RobertsonJ.F.R., BatesK., PearsonD., BlameyR.W., NicholsonR.I.Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer1992; 65: 727–30.
16.
MakrisA., AllredD.C., PowlesT.J.Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat1997; 44: 65–74.
17.
de NegriF., CampaniD., SarnelliR.Comparison of monoclonal immunocytochemical and immunoenzymatic methods for steroid receptor evaluation in breast cancer. Am J Clin Pathol1991; 96: 53–8.
18.
MolinoA., MiccioloR., TurazzaM.Prognostic significance of estrogen receptors in 405 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat1997; 45: 241–9.
19.
HarveyJ.M., ClarkG.M., OsborneC.K., AllredD.C.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endorine therapy in breast cancer. J Clin Oncol1999; 17: 1474–81.
20.
European Breast Cancer Collaborative Group.Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer1980; 16: 1513–5.
21.
VoogdA.C., CrommelinM.A., Repelaer van DrielO.J., Tutein Nolthenius-Puylaert MCBJE, VreugdenhilG., CoeberghJ.W.W.De betekenis van steroïdreceptoren voor de prognose en de hormonale behandeling van patiënten met mammacarcinoom: Een retrospectief onderzoek in Zuidoost-Nederland. Ned Tijdschr Geneeskd1998; 142: 1772–8.
22.
BernouxA., de CremouxP., Laine-BidronC., MartinE.C., AsselainB., MagdelénatH.Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome. Breast Cancer Res Treat1998; 49: 219–25.
23.
OsborneC.K.Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat1998; 51: 227–38.
24.
EstebanJ.M., BattiforaH., WarsiZ., BaileyA., BacusS.Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol1991; 4: 53–7.
25.
CourdiA., HeryM., ChauvelP., GioanniJ., NamerM., DemardF.Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cutoff level. Br J Cancer1988; 58: 88–90.
